LCM
AKBA icon

Laurion Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Laurion Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-99,321
Closed -$877K – 1078
2018
Q3 		$877K Sell
99,321
-416,186
-81% -$3.72M 0.01% 717
2018
Q2 		$5.14M Sell
515,507
-446,791
-46% -$4.47M 0.04% 344
2018
Q1 		$9.17M Buy
+962,298
New +$13.5M 0.07% 244
2017
Q3 		– Sell
-121,678
Closed -$1.75M – 1517
2017
Q2 		$1.75M Buy
+121,678
New +$1.54M 0.01% 849
2014
Q2 		– Sell
-22,975
Closed -$449K – 283
2014
Q1 		$449K Buy
+22,975
New +$484K 0.02% 194

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Laurion Capital Management's AKBA Position: Q4 2018 in Review

Laurion Capital Management sold out of Akebia Therapeutics (AKBA) in Q4 2018, closing a stake of 99,321 shares — an estimated $877K sold.

Laurion Capital Management first reported a position in AKBA in Q1 2014 and held it in 5 quarters. The position peaked at $9.17M in Q1 2018. 166 funds tracked by Wall St. Rank hold AKBA as of Q4 2018.

  • Laurion Capital Management reported no remaining Akebia Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Laurion Capital Management sold 99,321 Akebia Therapeutics shares in Q4 2018, an estimated $877K.
  • Laurion Capital Management first reported a position in Akebia Therapeutics in Q1 2014 and held it in 5 quarters.
  • Laurion Capital Management's Akebia Therapeutics position peaked at $9.17M in Q1 2018.
  • 166 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2018.

Based on Laurion Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.